therascreen FGFR RGQ RT-PCR Kit
RNA-based real-time PCR companion diagnostic for source-scoped FGFR3 alteration testing in urothelial cancer.
- Developer
- QIAGEN
- Intended use
- Other
- Cancer scope
- Urothelial cancer
- Specimen
- FFPE tumor tissue
- Molecular modality
- RNA
- Current version
- Current U.S. therascreen FGFR RGQ RT-PCR Kit source-defined configuration; IFU 06/2025, with four FGFR3 point mutations and two FGFR3-TACC3 fusions
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.